These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
225 related items for PubMed ID: 24652560
21. Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan. Coghill AE, Hsu WL, Pfeiffer RM, Juwana H, Yu KJ, Lou PJ, Wang CP, Chen JY, Chen CJ, Middeldorp JM, Hildesheim A. Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1213-9. PubMed ID: 24769890 [Abstract] [Full Text] [Related]
22. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients. Cui J, Yan W, Xu S, Wang Q, Zhang W, Liu W, Ni A. PLoS One; 2018 Jul; 13(3):e0193171. PubMed ID: 29494658 [Abstract] [Full Text] [Related]
23. Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening. Fachiroh J, Prasetyanti PR, Paramita DK, Prasetyawati AT, Anggrahini DW, Haryana SM, Middeldorp JM. J Clin Microbiol; 2008 Apr; 46(4):1374-80. PubMed ID: 18256216 [Abstract] [Full Text] [Related]
24. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients. Ayadi W, Karray-Hakim H, Feki L, Khabir A, Boudawara T, Ghorbel A, Daoud J, Frikha M, Hammami A. J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836 [Abstract] [Full Text] [Related]
25. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA. Yao JJ, Lin L, Jin YN, Wang SY, Zhang WJ, Zhang F, Zhou GQ, Cheng ZB, Qi ZY, Sun Y. Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915 [Abstract] [Full Text] [Related]
26. Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005. Kimura Y, Suzuki D, Tokunaga T, Takabayashi T, Yamada T, Wakisaka N, Yoshizaki T, Murata H, Miwa K, Shoujaku H, Watanabe Y, Yamada N, Ito Y, Yuta A, Takeuchi K, Hosokawa S, Mineta H, Hasegawa Y, Fujimoto Y, Nakashima T, Fujieda S. Auris Nasus Larynx; 2011 Apr; 38(2):244-9. PubMed ID: 20817430 [Abstract] [Full Text] [Related]
27. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease. Fachiroh J, Stevens SJ, Haryana SM, Middeldorp JM. J Virol Methods; 2010 Oct; 169(1):79-86. PubMed ID: 20621126 [Abstract] [Full Text] [Related]
28. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Leung SF, Tam JS, Chan AT, Zee B, Chan LY, Huang DP, Van Hasselt A, Johnson PJ, Lo YM. Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618 [Abstract] [Full Text] [Related]
29. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen. Mo WN, Tang AZ, Zhou L, Huang GW, Wang Z, Zeng Y. Chin Med J (Engl); 2009 May 20; 122(10):1173-8. PubMed ID: 19493466 [Abstract] [Full Text] [Related]
30. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Yu KJ, Hsu WL, Pfeiffer RM, Chiang CJ, Wang CP, Lou PJ, Cheng YJ, Gravitt P, Diehl SR, Goldstein AM, Chen CJ, Hildesheim A. Clin Cancer Res; 2011 Apr 01; 17(7):1906-14. PubMed ID: 21447725 [Abstract] [Full Text] [Related]
31. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM. Clin Vaccine Immunol; 2009 May 01; 16(5):706-11. PubMed ID: 19321695 [Abstract] [Full Text] [Related]
32. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma. Tiwawech D, Srivatanakul P, Karaluk A, Ishida T. Asian Pac J Cancer Prev; 2003 May 01; 4(2):113-8. PubMed ID: 12875623 [Abstract] [Full Text] [Related]
33. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China. Zheng XH, Lu LX, Li XZ, Jia WH. Cancer Sci; 2015 Sep 01; 106(9):1196-201. PubMed ID: 26082292 [Abstract] [Full Text] [Related]
34. Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma. Li RC, Du Y, Zeng QY, Tang LQ, Zhang H, Li Y, Liu WL, Zhong Q, Zeng MS, Huang XM. Oncotarget; 2016 Mar 29; 7(13):16372-83. PubMed ID: 27093005 [Abstract] [Full Text] [Related]
36. Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China. Chen H, Chen S, Lu J, Wang X, Li J, Li L, Fu J, Scheper T, Meyer W, Peng YH, Liu W. Cancer Prev Res (Phila); 2017 Sep 29; 10(9):542-550. PubMed ID: 28754665 [Abstract] [Full Text] [Related]